Phase 4 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been hospitalised or visited an emergency department due to acute (sudden or worsening) heart failure, diagnosed according to recognised international guidelines, based on typical symptoms and signs
- People with blood test results showing elevated natriuretic peptide levels (a marker the heart releases when under stress)
- People with any type of heart failure — whether the heart's pumping function is reduced, mildly reduced, or within normal range
- People for whom doctors have planned treatment with diuretics (fluid-removing medication) given through a drip (intravenously)
Who may not be able to join:
- People with Type 1 diabetes
- People who currently have a urinary tract or genital infection
- People whose body is low on fluids (hypovolemia)
- People with diabetic ketoacidosis (a serious diabetes complication)
- People whose blood sugar level is below 80 mg/dL at the time of enrolment
- People whose systolic (upper number) blood pressure is below 90 mmHg at the time of enrolment
- People with a known allergy or sensitivity to a class of diabetes medications called SGLT2 inhibitors
- People who are pregnant or breastfeeding
- People with a severe heart valve problem that requires a procedure or surgery
- People with severe liver disease (classified as Child-Pugh class C) (confirm with trial site)
- People whose kidneys are functioning below a certain level, specifically an estimated filtration rate under 25 mL/min/1.73 m² (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 002 01002662985
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Effect of Dapagliflozin on Pulmonary Congestion Assessed by Lung Ultrasound (LUS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.